Checkpoint Therapeutics Inc (CKPT) - Net Assets
Based on the latest financial reports, Checkpoint Therapeutics Inc (CKPT) has net assets worth $16.30 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($34.16 Million) and total liabilities ($17.87 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Checkpoint Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.30 Million |
| % of Total Assets | 47.7% |
| Annual Growth Rate | N/A |
| 5-Year Change | -135.69% |
| 10-Year Change | -127.21% |
| Growth Volatility | 75.93 |
Checkpoint Therapeutics Inc - Net Assets Trend (2014–2024)
This chart illustrates how Checkpoint Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore CKPT total asset value for the complete picture of this company's asset base.
Annual Net Assets for Checkpoint Therapeutics Inc (2014–2024)
The table below shows the annual net assets of Checkpoint Therapeutics Inc from 2014 to 2024. For live valuation and market cap data, see CKPT market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-12.62 Million | +3.23% |
| 2023-12-31 | $-13.05 Million | +33.03% |
| 2022-12-31 | $-19.48 Million | -165.50% |
| 2021-12-31 | $29.75 Million | -15.92% |
| 2020-12-31 | $35.38 Million | +87.72% |
| 2019-12-31 | $18.85 Million | +59.64% |
| 2018-12-31 | $11.81 Million | -21.51% |
| 2017-12-31 | $15.04 Million | -53.44% |
| 2016-12-31 | $32.30 Million | -30.37% |
| 2015-12-31 | $46.40 Million | -- |
| 2014-12-31 | $0.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Checkpoint Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 37057300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | % |
| Other Components | $357.94 Million | % |
| Total Equity | $-12.62 Million | 100.00% |
Checkpoint Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Checkpoint Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Van de Velde NV
BR:VAN
|
$367.83 Million |
|
Andes Technology Corp
TW:6533
|
$367.88 Million |
|
Kolte - Patil Developers Limited
NSE:KOLTEPATIL
|
$367.94 Million |
|
Mesabi Trust
NYSE:MSB
|
$368.15 Million |
|
Newtek Business Services Corp
NASDAQ:NEWT
|
$367.45 Million |
|
Zhangjiagang Haiguo New Energy Equipment Manufacturing Co. Ltd.
SHE:301063
|
$367.43 Million |
|
Jiangxi Hengda Hi-Tech Co Ltd
SHE:002591
|
$367.24 Million |
|
2CRSI S.A.
PA:AL2SI
|
$367.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Checkpoint Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -13,047,000 to -12,625,000, a change of 422,000.
- Net loss of 56,240,000 reduced equity.
- New share issuances of 26,000,000 increased equity.
- Other comprehensive income decreased equity by 3,419,000.
- Other factors increased equity by 34,081,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-56.24 Million | -445.47% |
| Share Issuances | $26.00 Million | +205.94% |
| Other Comprehensive Income | $-3.42 Million | -27.08% |
| Other Changes | $34.08 Million | +269.95% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Checkpoint Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $0.00 | $4.26 | x |
| 2015-12-31 | $18.99 | $4.26 | x |
| 2016-12-31 | $14.99 | $4.26 | x |
| 2017-12-31 | $6.65 | $4.26 | x |
| 2018-12-31 | $4.13 | $4.26 | x |
| 2019-12-31 | $5.34 | $4.26 | x |
| 2020-12-31 | $6.34 | $4.26 | x |
| 2021-12-31 | $3.91 | $4.26 | x |
| 2022-12-31 | $-2.21 | $4.26 | x |
| 2023-12-31 | $-0.70 | $4.26 | x |
| 2024-12-31 | $-0.32 | $4.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Checkpoint Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -137170.73%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-94.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -29.94% | -2354.58% | 0.01x | 1.09x | $-18.53 Million |
| 2016 | -69.53% | -873.97% | 0.07x | 1.11x | $-25.69 Million |
| 2017 | -150.77% | -1314.61% | 0.08x | 1.42x | $-24.18 Million |
| 2018 | -308.04% | -1037.28% | 0.14x | 2.11x | $-37.55 Million |
| 2019 | -130.41% | -1438.99% | 0.06x | 1.43x | $-26.46 Million |
| 2020 | -64.90% | -2147.90% | 0.03x | 1.20x | $-26.50 Million |
| 2021 | -190.33% | -21125.75% | 0.00x | 1.87x | $-59.59 Million |
| 2022 | 0.00% | -34851.56% | 0.01x | 0.00x | $-64.97 Million |
| 2023 | 0.00% | -50336.89% | 0.02x | 0.00x | $-50.54 Million |
| 2024 | 0.00% | -137170.73% | 0.01x | 0.00x | $-54.98 Million |
Industry Comparison
This section compares Checkpoint Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Checkpoint Therapeutics Inc (CKPT) | $16.30 Million | -29.94% | 1.10x | $367.72 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Checkpoint Therapeutics Inc
Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or m… Read more